{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T00:19:07Z","timestamp":1792887547955,"version":"4.5.0"},"reference-count":71,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T00:00:00Z","timestamp":1765756800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82300887"],"award-info":[{"award-number":["82300887"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004608","name":"Natural Science Foundation of Jiangsu Province","doi-asserted-by":"publisher","award":["BK20220717"],"award-info":[{"award-number":["BK20220717"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2022TQ0132"],"award-info":[{"award-number":["2022TQ0132"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017962","name":"Jiangsu Commission of Health","doi-asserted-by":"publisher","award":["K2023046"],"award-info":[{"award-number":["K2023046"]}],"id":[{"id":"10.13039\/100017962","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Renin-independent aldosterone secretion contributes to aldosteronism and heightened cardiovascular risk, but renin-independent aldosteronism is highly heterogenous. A refined classification may assist in identifying individuals with distinct cardiovascular risk profiles and guide individualized treatment strategies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Unsupervised hierarchical clustering was performed using 12 clinical parameters from patients with renin-independent aldosteronism in our registry cohort (n=404). The cluster centroids derived from the discovery cohort were fixed and applied to the Framingham Heart Study Third Generation cohort (n=417) for subject classification. The identified clusters were evaluated for their association with cardiovascular outcomes, assessed by echocardiographic parameters, serum biomarkers and cardiovascular event rates.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Three replicable clusters of patients with renin-independent aldosteronism were identified. Patients in cluster 2 showed the most severe metabolic abnormalities with the highest lipid and glucose levels, while patients in cluster 3 displayed the highest aldosterone levels. Both clusters 2 and 3 showed elevated baseline blood pressure and left ventricular remodeling compared with cluster 1. Cluster 2 exhibited the highest risk of cardiovascular disease, chronic heart failure and atrial fibrillation, followed by cluster 3, which showed a higher incidence of cardiovascular disease compared with cluster 1.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>We identified 3 subgroups with differing degrees of target organ damage and cardiovascular risk. Our findings establish metabolic dysfunction, rather than aldosterone excess, as a potential dominant cardiovascular risk driver in RIA patients, defining a new risk paradigm. Patients with renin-independent aldosteronism with metabolic dysfunction or high aldosterone levels may benefit from mineralocorticoid receptor antagonists with different priorities for metabolic and cardiovascular protection. This new refined classification may help tailor optimal treatment strategies for patients with heterogenous renin-independent aldosteronism.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2025.1686480","type":"journal-article","created":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T05:25:25Z","timestamp":1765776325000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Data-driven cluster analysis and external validation identify phenotypic subgroups in renin-independent aldosteronism with differential cardiovascular risk and therapeutic implications"],"prefix":"10.3389","volume":"16","author":[{"given":"Yuqing","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haifeng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutong","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maoting","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meiling","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,12,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18051032","article-title":"Aldosterone and mineralocorticoid receptors-physiology and pathophysiology","volume":"18","author":"Funder","year":"2017","journal-title":"Int J Mol Sci"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaf151","article-title":"Changes in parathyroid hormone across the spectrum of renin-independent aldosteronism","volume":"110","author":"Ooi","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.116.08952","article-title":"Continuum of renin-independent aldosteronism in normotension","volume":"69","author":"Baudrand","year":"2017","journal-title":"Hypertension"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.121.023082","article-title":"Heightened cardiovascular risk in hypertension associated with renin-independent aldosteronism versus renin-dependent aldosteronism: a collaborative study","volume":"10","author":"Hu","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2023.155593","article-title":"Renin-independent aldosteronism and chronic kidney disease in diabetes: Observational and Mendelian randomization analyses","volume":"145","author":"Hu","year":"2023","journal-title":"Metabolism"},{"key":"B6","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.clnu.2024.12.011","article-title":"Renin-independent aldosteronism and metabolic dysfunction-associated steatotic liver disease and cirrhosis: A genetic association study","volume":"44","author":"Zeng","year":"2025","journal-title":"Clin Nutr"},{"key":"B7","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/1043-2760(94)90090-6","article-title":"Renin-independent hypermineralocorticoidism","volume":"5","author":"Young","year":"1994","journal-title":"Trends Endocrinol Metab"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1093\/ajh\/hpy120","article-title":"Mineralocorticoid receptor and cardiovascular disease","volume":"31","author":"Buonafine","year":"2018","journal-title":"Am J Hypertens"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1210\/er.2018-00139","article-title":"The expanding spectrum of primary aldosteronism: implications for diagnosis, pathogenesis, and treatment","volume":"39","author":"Vaidya","year":"2018","journal-title":"Endocr Rev"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaf284","article-title":"Primary aldosteronism: an endocrine society clinical practice guideline","volume":"110","author":"Adler","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.7326\/M17-0882","article-title":"The spectrum of subclinical primary aldosteronism and incident hypertension: a cohort study","volume":"167","author":"Brown","year":"2017","journal-title":"Ann Internal Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.120.15006","article-title":"Serum aldosterone concentration, blood pressure, and coronary artery calcium: the multi-ethnic study of atherosclerosis","volume":"76","author":"Inoue","year":"2020","journal-title":"Hypertension"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.123.066389","article-title":"Subclinical primary aldosteronism and cardiovascular health: a population-based cohort study","volume":"149","author":"Hundemer","year":"2024","journal-title":"Circulation"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.120.050896","article-title":"Association of serum aldosterone and plasma renin activity with ambulatory blood pressure in African Americans: The Jackson Heart Study","volume":"143","author":"Joseph","year":"2021","journal-title":"Circulation"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.121.17336","article-title":"Relationship between the aldosterone-to-renin ratio and blood pressure in young adults: a longitudinal study","volume":"78","author":"Yang","year":"2021","journal-title":"Hypertension"},{"key":"B16","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1056\/NEJMoa033263","article-title":"Serum aldosterone and the incidence of hypertension in nonhypertensive persons","volume":"351","author":"Vasan","year":"2004","journal-title":"New Engl J Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.122.19134","article-title":"Cardiac structure and function across the spectrum of aldosteronism: the atherosclerosis risk in communities study","volume":"79","author":"Brown","year":"2022","journal-title":"Hypertension"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/s41371-023-00891-1","article-title":"Efficacy and safety of mineralocorticoid receptor antagonists for the treatment of low-renin hypertension: a systematic review and meta-analysis","volume":"38","author":"Shah","year":"2024","journal-title":"J Hum Hypertens"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1093\/ajh\/hpx066","article-title":"Physiological phenotyping for personalized therapy of uncontrolled hypertension in Africa","volume":"30","author":"Akintunde","year":"2017","journal-title":"Am J Hypertens"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/ajh.2010.98","article-title":"Plasma renin activity predicts blood pressure responses to beta-blocker and thiazide diuretic as monotherapy and add-on therapy for hypertension","volume":"23","author":"Turner","year":"2010","journal-title":"Am J Hypertens"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2019.11.006","article-title":"Mineralocorticoid receptors in metabolic syndrome: from physiology to disease","volume":"31","author":"Feraco","year":"2020","journal-title":"Trends Endocrinol Metab: TEM"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s001250050880","article-title":"Angiotensin II and the endocrine pancreas: effects on islet blood flow and insulin secretion in rats","volume":"41","author":"Carlsson","year":"1998","journal-title":"Diabetologia"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000127955.36250.65","article-title":"Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity","volume":"109","author":"Schupp","year":"2004","journal-title":"Circulation"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2005.05.051","article-title":"Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials","volume":"46","author":"Abuissa","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1001\/jama.290.21.2805","article-title":"A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial","volume":"290","author":"Pepine","year":"2003","journal-title":"JAMA"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1161\/01.hyp.23.4.450","article-title":"Kinins contribute to the improvement of insulin sensitivity during treatment with angiotensin converting enzyme inhibitor","volume":"23","author":"Tomiyama","year":"1994","journal-title":"Hypertension"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2010.04.024","article-title":"Effect of eplerenone versus spironolactone on cortisol and hemoglobin A1(c) levels in patients with chronic heart failure","volume":"160","author":"Yamaji","year":"2010","journal-title":"Am Heart J"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13809","article-title":"Effect of the mineralocorticoid receptor antagonist eplerenone on liver fat and metabolism in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial (MIRAD trial)","volume":"21","author":"Johansen","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1093\/eurjhf\/hfs067","article-title":"Eplerenone and new-onset diabetes in patients with mild heart failure: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF)","volume":"14","author":"Preiss","year":"2012","journal-title":"Eur J Heart Fail"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(24)00309-7","article-title":"Finerenone and new-onset diabetes in heart failure: a prespecified analysis of the FINEARTS-HF trial","volume":"13","author":"Butt","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/s41440-025-02143-w","article-title":"Metabolic phenotypes and fatty acid profiles associated with histopathology of primary aldosteronism","volume":"48","author":"Yang","year":"2025","journal-title":"Hypertens Res"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/s41569-019-0202-5","article-title":"70-year legacy of the framingham heart study","volume":"16","author":"Andersson","year":"2019","journal-title":"Nat Rev Cardiol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/S0140-6736(13)61752-3","article-title":"The Framingham Heart Study and the epidemiology of cardiovascular disease: a historical perspective","volume":"383","author":"Mahmood","year":"2014","journal-title":"Lancet"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.107.705202","article-title":"Parental occurrence of premature cardiovascular disease predicts increased coronary artery and abdominal aortic calcification in the Framingham Offspring and Third Generation cohorts","volume":"116","author":"Parikh","year":"2007","journal-title":"Circulation"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1093\/jn\/nxaa021","article-title":"Dairy intake in 2 American adult cohorts associates with novel and known targeted and nontargeted circulating metabolites","volume":"150","author":"Hruby","year":"2020","journal-title":"J Nutr"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1080\/09537104.2023.2238835","article-title":"Trends among platelet function, arterial calcium, and vascular function measures","volume":"34","author":"Cunha","year":"2023","journal-title":"Platelets"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Internal Med"},{"key":"B38","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/EJE-19-0893","article-title":"European society of endocrinology clinical practice guideline: Endocrine work-up in obesity","volume":"182","author":"Pasquali","year":"2020","journal-title":"Eur J Endocrinol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0000000000001855","article-title":"Development and validation of subtype prediction scores for the workup of primary aldosteronism","volume":"36","author":"Kobayashi","year":"2018","journal-title":"J Hypertens"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyv337","article-title":"Cohort Profile: The Framingham Heart Study (FHS): overview of milestones in cardiovascular epidemiology","volume":"44","author":"Tsao","year":"2015","journal-title":"Int J Epidemiol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehac446","article-title":"Dietary metabolic signatures and cardiometabolic risk","volume":"44","author":"Shah","year":"2023","journal-title":"Eur Heart J"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.107.699579","article-title":"General cardiovascular risk profile for use in primary care: the Frami ngham Heart Study","volume":"117","author":"D\u2019Agostino","year":"2008","journal-title":"Circulation"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.116.015140","article-title":"Stroke and circulating extracellular RNAs","volume":"48","author":"Mick","year":"2017","journal-title":"Stroke"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197112232852601","article-title":"The natural history of congestive heart failure: the Framingham study","volume":"285","author":"McKee","year":"1971","journal-title":"New Engl J Med"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61774-8","article-title":"50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study","volume":"386","author":"Schnabel","year":"2015","journal-title":"Lancet"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehad375","article-title":"New-onset atrial fibrillation prediction: the HARMS2-AF risk score","volume":"44","author":"Segan","year":"2023","journal-title":"Eur Heart J"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.echo.2014.10.003","article-title":"Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"28","author":"Lang","year":"2015","journal-title":"J Am Soc Echocardiogr"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.55.4.613","article-title":"Echocardiographic determination of left ventricular mass in man","volume":"55","author":"Devereux","year":"1977","journal-title":"Anat Validation Method Circ"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2020.12.088","article-title":"Circulating growth factors and cardiac remodeling in the community: The Framingham Heart Study","volume":"329","author":"Castro-Diehl","year":"2021","journal-title":"Int J Cardiol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.117.028201","article-title":"Age-related autonomous aldosteronism","volume":"136","author":"Nanba","year":"2017","journal-title":"Circulation"},{"key":"B51","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1210\/clinem\/dgaa484","article-title":"International histopathology consensus for unilateral primary aldosteronism","volume":"106","author":"Williams","year":"2021","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"B52","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.tem.2021.10.002","article-title":"Pathophysiology and histopathology of primary aldosteronism","volume":"33","author":"Williams","year":"2022","journal-title":"Trends Endocrinol Metab: TEM"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.115.018226","article-title":"Adipocyte-derived hormone leptin is a direct regulator of aldosterone secretion, which promotes endothelial dysfunction and cardiac fibrosis","volume":"132","author":"Huby","year":"2015","journal-title":"Circulation"},{"key":"B54","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/nature13474","article-title":"Lipid landscapes and pipelines in membrane homeostasis","volume":"510","author":"Holthuis","year":"2014","journal-title":"Nature"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2025.103498","article-title":"EGR1 regulates oxidative stress and aldosterone production in adrenal cells and aldosterone-producing adenomas","volume":"80","author":"Pang","year":"2025","journal-title":"Redox Biol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.jlr.2022.100191","article-title":"The role of lipid second messengers in aldosterone synthesis and secretion","volume":"63","author":"Spaulding","year":"2022","journal-title":"J Lipid Res"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-22-0040","article-title":"The metabolic phenotype of patients with primary aldosteronism: impact of subtype and sex - a multicenter-study of 3566 Caucasian and Asian subjects","volume":"187","author":"Spyroglou","year":"2022","journal-title":"Eur J Endocrinol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-00866","article-title":"Obesity as a key factor underlying idiopathic hyperaldosteronism","volume":"103","author":"Ohno","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1093\/ajh\/hpt276","article-title":"Association of renin and aldosterone with ethnicity and blood pressure: the Multi-Ethnic Study of Atherosclerosis","volume":"27","author":"Rifkin","year":"2014","journal-title":"Am J Hypertens"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0000000000003377","article-title":"The effect of age, sex and BMI on the aldosterone-to-renin ratio in essential hypertensive individuals","volume":"41","author":"Alnazer","year":"2023","journal-title":"J Hypertens"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.124.070039","article-title":"Relationship between renin, aldosterone, aldosterone-to-renin ratio and arterial stiffness and left ventricular mass index in young adults","volume":"150","author":"Ananda","year":"2024","journal-title":"Circulation"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.120.15026","article-title":"2020 International Society of Hypertension global hypertension practice guidelines","volume":"75","author":"Unger","year":"2020","journal-title":"Hypertension"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.124.23962","article-title":"Efficacy and safety of aldosterone synthase inhibitors for hypertension: a meta-analysis of randomized controlled trials and systematic review","volume":"82","author":"Marzano","year":"2025","journal-title":"Hypertension"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaa736","article-title":"Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine","volume":"42","author":"Agarwal","year":"2021","journal-title":"Eur Heart J"},{"key":"B65","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1161\/HYPERTENSIONAHA.117.10360","article-title":"Selective mineralocorticoid receptor cofactor modulation as molecular basis for finerenone\u2019s antifibrotic activity","volume":"71","author":"Grune","year":"2018","journal-title":"Hypertension"},{"key":"B66","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/164_2016_76","article-title":"Steroidal and novel non-steroidal mineralocorticoid receptor antagonists in heart failure and cardiorenal diseases: comparison at bench and bedside","volume":"243","author":"Kolkhof","year":"2017","journal-title":"Handb Exp Pharmacol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2024.10.111","article-title":"Finerenone, obesity, and heart failure with mildly reduced\/preserved ejection fraction: prespecified analysis of FINEARTS-HF","volume":"85","author":"Butt","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.124.071452","article-title":"Efficacy and safety of finerenone in patients with primary aldosteronism: a pilot randomized controlled trial","volume":"151","author":"Hu","year":"2025","journal-title":"Circulation"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.2337\/dc24-1873","article-title":"Efficacy and safety of finerenone in type 2 diabetes: a pooled analysis of trials of heart\u00a0failure and chronic kidney disease","volume":"48","author":"Ostrominski","year":"2025","journal-title":"Diabetes Care"},{"key":"B71","doi-asserted-by":"publisher","first-page":"33","DOI":"10.2337\/dc24-1873","article-title":"Aldosterone, renin, and aldosterone-to-renin ratio variability in screening for primary aldosteronism","volume":"108","author":"Ng","year":"2022","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1686480\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T05:25:26Z","timestamp":1765776326000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1686480\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,15]]},"references-count":71,"alternative-id":["10.3389\/fendo.2025.1686480"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2025.1686480","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,15]]},"article-number":"1686480"}}